Abstract: Provided is a novel cancer treatment means in which a reversible BTK inhibitor and immunity checkpoint inhibitor are combined. For example, provided is a pharmaceutical composition for treating cancer wherein BTK inhibitor (I-A) and anti PD-1 antibody are combined.

Abstract: An oxoisoquinoline compound of the following formula: or a pharmaceutically acceptable salt thereof; a pharmaceutical composition comprising the oxoisoquinoline compound or salt; and a method for treating B-cell lymphoma comprising administering the oxoisoquinoline compound or salt to a patient.

Abstract: The present invention provides with an oxoisoquinoline derivative represented by the formula (I) (in the formula, Q and R1 are as defined in the description) or a pharmaceutically acceptable salt thereof, which is useful as a Bruton's kinase inhibitor for treating cancer, B-cell lymphoma, chronic lymphocytic leukemia and the like.

Abstract: The present invention provides a quinazoline derivative represented by the following formula (I): wherein R1 and R2 represent a hydrogen atom, a halogen atom, or a lower alkyl group optionally having a substituent; Z represents a cycloalkyl group having a substituent or a cycloalkenyl group having a substituent; and Q represents a bicyclic heteroaryl group optionally having a substituent, or a pharmaceutically acceptable salt thereof. Since the compound has an inhibitory effect on the Wnt/?-catenin signaling pathway and exhibits an antitumor effect, it is useful as a medicine.

Abstract: The present invention provides a quinazoline derivative represented by the following formula (I): wherein R1 and R2 represent a hydrogen atom, a halogen atom, or a lower alkyl group optionally having a substituent; Z represents a cycloalkyl group having a substituent or a cycloalkenyl group having a substituent; and Q represents a bicyclic heteroaryl group optionally having a substituent, or a pharmaceutically acceptable salt thereof. Since the compound has an inhibitory effect on the Wnt/?-catenin signaling pathway and exhibits an antitumor effect, it is useful as a medicine.

Abstract: This invention relates to pyridone-carboxylic acid derivatives of the following formula or salts thereof: ##STR1## wherein R.sub.1 is a hydrogen atom, a halogen atom, etc.,R.sub.2 is a carboxyl group etc.,R.sub.3 is a hydrogen atom etc.,A is a nitrogen atom or CH,m is 1 or 2, andY is an eliminable group or a group having the following formula: ##STR2## wherein R.sub.4 is a hydrogen atom or a lower alkyl group,Z is a hydrogen atom, a lower alkyl group, etc.,R.sub.5 is a hydrogen atom, a lower alkyl group, etc.,n is 0 or 1, andp is 1, 2, 3 or 4and to processes for the preparation of these compounds, and further to anti-tumor agents which contain the above compounds as effective ingredients.

Abstract: A method of preventing or eliminating mycoplasma contamination of animal or plant cell cultures, which comprises adding an anti-mycoplasmally effective amount of 5-amino-7-(2-aminomethylmorpholino)-1-cyclopropyl-6, 8-difluoro-1,4-dihydro-4-oxoquinoline-3-carboxylic acid or its salt to a culture medium in which animal or plant cells are cultivated; and an agent or a preparation for preventing or eliminating mycoplasma contamination of animal or plant cell cultures, comprising 5-amino-7-(2-aminomethylmorpholino)-1-cyclopropyl-6, 8-difluoro-1,4-dihydro-4-oxoquinoline-3-carboxylic acid or its salt.